The impact of hyperbaric oxygen treatment for cardiovascular implantable electronic devices

被引:0
|
作者
Goto, Kentaro [1 ,3 ]
Miyazaki, Shinsuke [1 ]
Oyaizu, Takuya [2 ]
Negishi, Miho [1 ]
Ikenouchi, Takashi [1 ]
Yamamoto, Tasuku [1 ]
Kawamura, Iwanari [1 ]
Nishimura, Takuro [1 ]
Takamiya, Tomomasa [1 ]
Tao, Susumu [1 ]
Takigawa, Masateru [1 ]
Yagishita, Kazuyoshi [2 ]
Sasano, Tetsuo [1 ]
机构
[1] Tokyo Med & Dent Univ Hosp, Dept Cardiovasc Med, Tokyo, Japan
[2] Tokyo Med & Dent Univ Hosp, Dept Hyperbar, Med Ctr, Tokyo, Japan
[3] Tokyo Med & Dent Univ, Dept Cardiovasc Med, 1-5-45 Yushima,Bunkyo ku, Tokyo 1138510, Japan
关键词
cardiovascular implantable electronic devices; hyperbaric oxygen treatment; CARDIOPULMONARY-RESUSCITATION; THERAPY;
D O I
10.1002/joa3.13070
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
IntroductionThe safety of hyperbaric oxygen treatment (HBO2) in patients with cardiovascular implanted electronic devices (CIED) remains unclear.MethodsWe conducted a retrospective analysis of seven CIED patients (median age 79 [73-83] years, five males [71.4%]), including five with pacemakers and two with implantable cardioverter defibrillators (ICD), who underwent HBO2 between June 2013 and April 2023. During the initial session, electrocardiogram monitoring was conducted, and CIED checks were performed before and after the treatment. In addition, the medical records were scrutinized to identify any abnormal CIED operations.ResultsAll seven CIED patients underwent HBO2 within the safety pressure range specified by the CIED manufacturers or general pressure test by the International Organization for Standardization (2.5 [2.5-2.5] atmosphere absolute x 18 [5-20] sessions). When comparing the CIED parameters before and after HBO2, no significant changes were observed in the waveform amplitudes, pacing thresholds, lead impedance of the atrial and ventricular leads, or battery levels. All seven patients, including two with the rate response function activated, exhibited no significant changes in the pacing rate or pacing failure. Two ICD patients did not deactivate the therapy, including the defibrillation; however, they did not experience any arrhythmia or inappropriate ICD therapy during the HBO2.ConclusionCIED patients who underwent HBO2 within the safety pressure range exhibited no significant changes in the parameters immediately after the HBO2 and had no observable abnormal CIED operations during the treatment. The safety of defibrillation by an ICD during HBO2 should be clarified. The patients with CIEDs who underwent HBO2 within the safety pressure range specified by the ICD manufacturers showed no significant changes in the CIED parameters before or immediately after HBO2, and there were no observable abnormalities in the CIED operation during HBO2.image
引用
收藏
页码:958 / 964
页数:7
相关论文
共 50 条
  • [21] Current impact of cardiac implantable electronic devices
    Kuschyk, J.
    Rudic, B.
    Borggrefe, M.
    Akin, I.
    HERZ, 2017, 42 (02) : 151 - 161
  • [22] The Role of Cardiovascular Implantable Electronic Devices in the Detection and Treatment of Subclinical Atrial Fibrillation A Review
    Hess, Paul L.
    Healey, Jeff S.
    Granger, Christopher B.
    Connolly, Stuart J.
    Ziegler, Paul D.
    Alexander, John H.
    Kowey, Peter R.
    Ruff, Christian T.
    Flaker, Greg
    Halperin, Jonathan L.
    Hart, Robert G.
    Lopes, Renato D.
    JAMA CARDIOLOGY, 2017, 2 (03) : 324 - 331
  • [23] Treatment of Infected Cardiac Implantable Electronic Devices
    Fakhro, Abdulla
    Jalalabadi, Faryan
    Brown, Rodger H.
    Izaddoost, Shayan A.
    SEMINARS IN PLASTIC SURGERY, 2016, 30 (02) : 60 - 65
  • [24] Austrian recommendations for aftercare of cardiovascular implantable electronic devices (CIED)
    Burkart-Kuettner, D.
    Nuernberg, M.
    JOURNAL FUR KARDIOLOGIE, 2023, 30 (9-10): : 229 - 207
  • [25] Adhesive strips for wound closure of cardiovascular implantable electronic devices
    Lacquaniti, Aldo
    Salvi, Fabio
    Russo, Antonella
    Marcheselli, Andrea
    De Rosa, Rosario
    Caroselli, Costantino
    JOURNAL OF CARDIOVASCULAR MEDICINE, 2022, 23 (09) : 626 - 628
  • [26] Development of cardiovascular implantable electronic devices - A history of trouble shooting
    Ishikawa, Toshiyuki
    JOURNAL OF ARRHYTHMIA, 2014, 30 (02) : 75 - 76
  • [27] Determining the Safety of Radiofrequency Ablation in Cardiovascular Implantable Electronic Devices
    Jabri, Ahmad
    Butt, Muhammad Umer
    Haddadin, Faris
    Alhuneafat, Laith
    Al Abdouh, Ahmad
    Mhanna, Mohammed
    Kumar, Ashish
    Nasser, Farhan
    Elhamdani, Adee
    Abu Jazar, Deaa
    Yousaf, Adnan
    Hamade, Hani
    Nabeel, Yassar
    Almahameed, Soufian
    CURRENT PROBLEMS IN CARDIOLOGY, 2022, 47 (10)
  • [28] Management of bacteremia in patients living with cardiovascular implantable electronic devices
    DeSimone, Daniel C.
    Sohail, M. Rizwan
    HEART RHYTHM, 2016, 13 (11) : 2247 - 2252
  • [29] Disseminated malignancies masquerading as cardiovascular implantable electronic devices infections
    Kojodjojo, Pipin
    John, Roy M.
    Epstein, Laurence M.
    EUROPACE, 2011, 13 (06): : 821 - 824
  • [30] Salvage of infected cardiovascular implantable electronic devices by a novel therapy
    Topaz, M.
    Kazatsker, M.
    Shotan, A.
    Carmel, N.
    Silberman, A.
    Oron, Y.
    EUROPEAN HEART JOURNAL, 2012, 33 : 243 - 244